Related Experiment Videos
[Inhibition of basal acid secretion by trimethyldesoxy-prostaglandin E2 in humans]
Arzneimittel-Forschung
|January 1, 1983
Abstract:
The effect of graded oral doses of trimethyldesoxy-prostaglandin E2 (Ro 21-6937) on basal acid secretion in healthy volunteers was tested over a time period of 6 h. Basal acid output was reduced by 80% after 1500 micrograms Ro 21-6937. Half-maximal inhibition was achieved by 700 micrograms Ro 21-6937. 250 micrograms of this prostaglandin E2 analog showed no detectable antisecretory activity.
Insights
Trimethyldesoxy-prostaglandin E2 (Ro 21-6937) effectively reduced gastric acid secretion in healthy individuals. Doses of 700 micrograms achieved half-maximal inhibition, with 1500 micrograms reducing acid output by 80%.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Prostaglandins play a role in regulating gastric acid secretion.
- Investigating novel prostaglandin analogs for antisecretory effects is crucial for developing new treatments.
Purpose of the Study:
- To evaluate the antisecretory effect of graded oral doses of trimethyldesoxy-prostaglandin E2 (Ro 21-6937) on basal gastric acid secretion in healthy volunteers.
Main Methods:
- Healthy volunteers received varying oral doses of trimethyldesoxy-prostaglandin E2 (Ro 21-6937).
- Basal gastric acid secretion was measured over a 6-hour period.
- Dose-response relationship was analyzed to determine efficacy.
Main Results:
- Trimethyldesoxy-prostaglandin E2 (Ro 21-6937) demonstrated a dose-dependent reduction in basal acid output.
- A dose of 1500 micrograms resulted in an 80% reduction in acid secretion.
- Half-maximal inhibition of acid secretion was observed at approximately 700 micrograms.
Conclusions:
- Trimethyldesoxy-prostaglandin E2 (Ro 21-6937) is a potent inhibitor of gastric acid secretion.
- The compound shows potential as a therapeutic agent for conditions involving excessive acid production.
- Lower doses (250 micrograms) did not exhibit significant antisecretory activity.